Diabetes is at epidemic levels, and over 29 million people in the U.S. alone suffer from this disease.
What some of them don't do, however, is keep a check on their eyes.
All people with diabetes, both type-1 and type-2, are at risk for diabetic vision loss.
A recent report published in Med Scape showed how this demographic is prone to skipping their eye exams.
In the Spring of 2015, the FDA approved a first-of-its-kind implant called Iluvien that slowly releases medication for three years, eliminating the burden/expense of monthly visits, as well as the emotional impact of worrying when the vision loss will return.
What do you need to know about Iluvien?
Nancy Holecamp, MD, joins Melanie Cole, MS, to discuss diabetes blindness and this new medication that can reduce vision loss.